MX2021004134A - Benzoxazol y compuestos relacionados útiles como moduladores de autofagia mediada por chaperonas. - Google Patents
Benzoxazol y compuestos relacionados útiles como moduladores de autofagia mediada por chaperonas.Info
- Publication number
- MX2021004134A MX2021004134A MX2021004134A MX2021004134A MX2021004134A MX 2021004134 A MX2021004134 A MX 2021004134A MX 2021004134 A MX2021004134 A MX 2021004134A MX 2021004134 A MX2021004134 A MX 2021004134A MX 2021004134 A MX2021004134 A MX 2021004134A
- Authority
- MX
- Mexico
- Prior art keywords
- chaperone
- benzoxazole
- compounds useful
- related compounds
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862743920P | 2018-10-10 | 2018-10-10 | |
| PCT/US2019/055493 WO2020077024A1 (en) | 2018-10-10 | 2019-10-10 | Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021004134A true MX2021004134A (es) | 2021-07-16 |
Family
ID=70163886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004134A MX2021004134A (es) | 2018-10-10 | 2019-10-10 | Benzoxazol y compuestos relacionados útiles como moduladores de autofagia mediada por chaperonas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12473266B2 (https=) |
| EP (1) | EP3863755A4 (https=) |
| JP (1) | JP7503850B2 (https=) |
| KR (1) | KR20210082466A (https=) |
| CN (1) | CN113195084B (https=) |
| AU (1) | AU2019358074A1 (https=) |
| BR (1) | BR112021006843A2 (https=) |
| CA (1) | CA3115297A1 (https=) |
| IL (1) | IL282069A (https=) |
| MX (1) | MX2021004134A (https=) |
| WO (1) | WO2020077024A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022015624A1 (en) * | 2020-07-16 | 2022-01-20 | Schrödinger, Inc. | Substituted dihydropyrazinediones as modulators of the nmda receptor |
| CN116438166A (zh) * | 2020-11-20 | 2023-07-14 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的n-取代4-(1,3-芳基并噁唑-2-基)苯基化合物 |
| WO2022155333A1 (en) * | 2021-01-13 | 2022-07-21 | Albert Einstein College Of Medicine | Use of chaperone-mediated autophagy activators for treating or preventing blood cancers and myelodysplastic syndromes |
| KR102778740B1 (ko) | 2021-06-24 | 2025-03-07 | 주식회사 엘지화학 | 합성가스의 제조방법 |
| CN114404421B (zh) * | 2022-02-28 | 2023-04-28 | 同济大学 | 选择性自噬激活剂qx77在制备干预或治疗糖尿病视网膜病变的药物中的应用 |
| WO2024225738A1 (ko) * | 2023-04-25 | 2024-10-31 | 부산대학교 산학협력단 | 지방간질환 치료 또는 예방 목적의 fxr/ppar alpha 이중 작용 활성을 가지는 벤즈옥사졸 유도체 화합물 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH469802A (de) * | 1966-01-07 | 1969-03-15 | Ciba Geigy | Verwendung von Benzoxazol-Derivaten als Scintillator-Substanzen |
| US5428052A (en) * | 1984-09-19 | 1995-06-27 | Centre Internationale De Recherches Dermatologiques (C.I.R.D.) | Aromatic heterocyclic derivatives and their therapeutic and cosmetic use |
| JP3969741B2 (ja) * | 1995-11-17 | 2007-09-05 | マーク アンド カンパニー インコーポレイテッド | アセチルコリン受容体の修飾因子として役立つ新規置換アリール化合物 |
| WO2003048137A1 (en) | 2001-11-30 | 2003-06-12 | Merck & Co., Inc. | Metabotropic glutamate receptor-5 modulators |
| CN1636037A (zh) | 2002-02-21 | 2005-07-06 | 西巴特殊化学品控股有限公司 | 基于内酰胺的颜料及其在生产有色塑料或聚合有色颗粒中的应用 |
| PL1745041T3 (pl) | 2004-04-30 | 2012-11-30 | Genentech Inc | Inhibitory chinoksalinowe szlaku sygnałowego hedgehog |
| NZ552397A (en) * | 2004-07-15 | 2011-04-29 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| JP5301999B2 (ja) | 2005-10-31 | 2013-09-25 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｃｅｔｐ阻害薬 |
| RU2462458C2 (ru) * | 2006-02-10 | 2012-09-27 | Байомарин Ига Лимитед | Лечение миодистрофии дюшена |
| CA2641880C (en) * | 2006-02-10 | 2014-09-09 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| GB0602768D0 (en) * | 2006-02-10 | 2006-03-22 | Vastox Plc | Treatment of muscular dystrophy |
| AR066879A1 (es) | 2007-06-08 | 2009-09-16 | Novartis Ag | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus |
| CA2685540C (en) | 2007-08-03 | 2018-10-16 | Graham Michael Wynne | Drug combinations for the treatment of duchenne muscular dystrophy |
| CA2737028C (en) | 2008-09-23 | 2017-06-27 | Wista Laboratories Ltd. | Ligands for aggregated tau molecules |
| JP2011168515A (ja) | 2010-02-17 | 2011-09-01 | Kowa Co | エリスロポエチン産生促進作用を有する２−アリールベンゾオキサゾール化合物 |
| US9512092B2 (en) * | 2013-12-12 | 2016-12-06 | Albert Einstein College Of Medicine, Inc. | Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof |
| EP3187495A1 (en) * | 2015-12-30 | 2017-07-05 | Johannes Gutenberg-Universität Mainz | 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment |
| WO2017160116A2 (ko) * | 2016-03-17 | 2017-09-21 | 연세대학교 산학협력단 | 니코틴아미드 포스포리보실트랜스퍼라제 억제용 신규 화합물 및 이를 포함하는 조성물 |
| JP2018087173A (ja) | 2016-11-29 | 2018-06-07 | 国立大学法人北海道大学 | 悪性脳腫瘍治療薬 |
| JP7101678B2 (ja) | 2016-12-22 | 2022-07-15 | インサイト・コーポレイション | 免疫調節剤としての複素環式化合物 |
| US10676467B2 (en) | 2017-06-30 | 2020-06-09 | Washington University | Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof |
-
2019
- 2019-10-10 CN CN201980081709.XA patent/CN113195084B/zh active Active
- 2019-10-10 EP EP19871950.2A patent/EP3863755A4/en active Pending
- 2019-10-10 WO PCT/US2019/055493 patent/WO2020077024A1/en not_active Ceased
- 2019-10-10 KR KR1020217013722A patent/KR20210082466A/ko not_active Ceased
- 2019-10-10 US US17/283,613 patent/US12473266B2/en active Active
- 2019-10-10 CA CA3115297A patent/CA3115297A1/en active Pending
- 2019-10-10 BR BR112021006843-0A patent/BR112021006843A2/pt unknown
- 2019-10-10 AU AU2019358074A patent/AU2019358074A1/en not_active Abandoned
- 2019-10-10 JP JP2021519763A patent/JP7503850B2/ja active Active
- 2019-10-10 MX MX2021004134A patent/MX2021004134A/es unknown
-
2021
- 2021-04-05 IL IL282069A patent/IL282069A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3115297A1 (en) | 2020-04-16 |
| WO2020077024A1 (en) | 2020-04-16 |
| JP7503850B2 (ja) | 2024-06-21 |
| IL282069A (en) | 2021-05-31 |
| EP3863755A4 (en) | 2022-08-03 |
| CN113195084B (zh) | 2024-04-09 |
| AU2019358074A1 (en) | 2021-05-06 |
| JP2022504650A (ja) | 2022-01-13 |
| US20210387953A1 (en) | 2021-12-16 |
| CN113195084A (zh) | 2021-07-30 |
| US12473266B2 (en) | 2025-11-18 |
| KR20210082466A (ko) | 2021-07-05 |
| EP3863755A1 (en) | 2021-08-18 |
| BR112021006843A2 (pt) | 2021-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021004134A (es) | Benzoxazol y compuestos relacionados útiles como moduladores de autofagia mediada por chaperonas. | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| CL2021001461A1 (es) | Moduladores de trex1 | |
| UY35818A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
| CO2017009614A2 (es) | Compuestos bicíclicos de sulfonamida cetona | |
| MX2017005668A (es) | Nuevos compuestos de acido carboxilico utiles para inhibir la sintasa-1 de prostaglandina microsomal e2. | |
| AR121047A1 (es) | Inhibidores de map4k1 | |
| EA201891703A1 (ru) | Соединения бензопиразола и их аналоги | |
| EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
| CU20160188A7 (es) | Compuestos de indazole substituidos como inhibidores de irak4 | |
| UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| PH12015502036A1 (en) | Inhibitors of the kynurenine pathway | |
| MX2016012145A (es) | Composicion de control de enfermedades de plantas y metodo para controlar enfermedades de plantas mediante su aplicacion. | |
| NI201700056A (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer | |
| UY36716A (es) | Moduladores de receptores nucleares | |
| CL2021000844A1 (es) | Compuestos de indolinona para uso como inhibidores de map4k1 | |
| ECSP16072941A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| MX2021009806A (es) | Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos. | |
| DOP2019000193A (es) | Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende | |
| NI201700055A (es) | 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| CL2017002745A1 (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
| EA201791259A1 (ru) | Производные пиперидина в качестве ингибиторов hdac1/2 | |
| MX2021012305A (es) | Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1. | |
| EA201790496A1 (ru) | Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm |